RT Journal Article
SR Electronic
T1 First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e007227
DO 10.1136/jitc-2023-007227
VO 12
IS 2
A1 Ren, Shengxiang
A1 Wang, Xicheng
A1 Han, Bao-Hui
A1 Pan, Yueyin
A1 Zhao, Jun
A1 Cheng, Yufeng
A1 Hu, Sheng
A1 Liu, Tianshu
A1 Li, Yalun
A1 Cheng, Ying
A1 Feng, Jifeng
A1 Yi, Shanyong
A1 Gu, Shanzhi
A1 Gao, Shegan
A1 Luo, Yongzhong
A1 Liu, Ying
A1 Liu, Caigang
A1 Duan, Huijie
A1 Wang, Shuni
A1 Yang, Xinfeng
A1 Fan, Jia
A1 Zhou, Caicun
YR 2024
UL http://jitc.bmj.com/content/12/2/e007227.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.